Testing for erbB-2 by Immunohistochemistry in Breast Cancer
Open Access
- 1 February 2000
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 113 (2), 171-175
- https://doi.org/10.1309/9x6x-1el6-5qb1-yld2
Abstract
D. Craig Allred, MD, Paul E. Swanson, MD; Testing for erbB-2 by Immunohistochemistry in Breast Cancer, American Journal of Clinical Pathology, Volume 113, IssuKeywords
This publication has 23 references indexed in Scilit:
- HER-2/neu Protein Expression in Breast Cancer Evaluated by ImmunohistochemistryAmerican Journal of Clinical Pathology, 2000
- Is ERBB-2 A predictive marker for response to primary chemotherapy for operable breast cancer: a prospective study in a phase ii randomized trial of doxorubicin/cyclophosphamide (AC) and doxorubicin/paclitaxel (AT)European Journal Of Cancer, 1999
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor MarkersJNCI Journal of the National Cancer Institute, 1996
- The significance ofheregulin in breast cancer tumor progression and drug resistanceBreast Cancer Research and Treatment, 1996
- c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancerEuropean Journal Of Cancer, 1995
- The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A reviewGene, 1995
- ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancerCancer Letters, 1994
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancerInternational Journal of Cancer, 1991
- Breast Cancer Prognostic Factors: Evaluation GuidelinesJNCI Journal of the National Cancer Institute, 1991